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Abstract
Background: Artesunate plus amodiaquine is a coblistered ACT, given as a single daily intake. It has been suggested that, in
view of the number of tablets to be taken (particularly in adults), it may be possible to improve compliance by allowing patients
to divide the daily dose. The objectives of this randomized, comparative, open-label, multicentre study, conducted in Senegal
and in Cameroon in 2005, was to demonstrate the non-inferiority and to compare the safety of artesunate plus amodiaquine,
as a single daily intake versus two daily intakes.
Methods: A three-day treatment period and 14-day follow-up period was performed in any subject weighting more than 10 kg,
presenting with a malaria paroxysm confirmed by parasitaemia ≥ 1,000/μl, after informed consent. Patients were randomly
allocated into one of the two regimens, with dosage according to bodyweight range. All products were administered by an
authorized person, blinded to both the investigating physician and the biologist. The primary endpoint was an adequate response
to treatment on D14 (WHO definition). The two-sided 90% confidence interval of the difference was calculated on intent to
treat (ITT) population; the acceptance limit for non-inferiority was 3%. The safety was evaluated by incidence of adverse events.
Results: Three-hundred and sixteen patients were included in the study. The two patient groups were strictly comparable on
D0. The adequate responses to treatment were similar for the two treatment regimens on D14, PCR-corrected (99,4% in the
one-daily intake group versus 99,3% in the comparative group). The statistical analyses demonstrated the non-inferiority of
administering artesunate/amodiaquine as two intakes. The drug was well tolerated. The main adverse events were
gastrointestinal disorders (2.5%) and pruritus (2.5%); safety profiles were similar in the two groups.
Conclusion: This pilot study confirms the efficacy and good tolerability of artesunate plus amodiaquine, administrated either
in one or in two daily intakes.
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Background
Nearly all currently available antimalarial monotherapies
are facing resistance, the severity and incidence of which
may vary according to endemic areas. Only one class of
antimalarials, artemisinin derivatives and artesunate in
particular, has been able to escape this phenomenon so
far, most probably owing to its recent introduction, its
mechanism of action and its rapid elimination from the
body. National and international experts, in agreement
with the WHO [1], have proposed a treatment option
combining antimalarial agents with a prolonged schizon-
ticidal effect with an oral artemisinin derivative for the
treatment of uncomplicated Plasmodium falciparum
attacks.
The onset of resistance to this type of treatment combina-
tion is unlikely, partly because the combined agents have
different mechanisms of action, and also because the
artemisinin derivative very rapidly reduces the parasite
biomass which enables lasting exposure of the few
remaining parasites to a high concentration of the com-
bined drug.
A number of controlled phase III studies under the aus-
pices of the TDR [2], together with a number of large-scale
studies [3] have investigated bitherapy with artesunate
combined with amodiaquine. This well-tolerated combi-
nation in no way increases the possible undesirable effects
arising from amodiaquine alone, but improves the cure
rates in countries where the latter antimalarial has become
less effective. Phase IV studies, conducted in Senegal, the
Comoros and Mali in over 1,000 patients, have confirmed
its efficacy in the region of 95 to 99%, and its good clinical
and biological safety.
Bitherapy with artesunate and amodiaquine has obtained
a marketing authorization in several African countries,
including Senegal and Cameroon, under the Arsucam®
trademark.
Artesunate plus amodiaquine was evaluated as a single
daily intake in all of the studies already performed. The
number of tablets to be taken for each intake (particularly
in adults: eight tablets per intake) suggests that compli-
ance may be improved by allowing patients to divide tab-
let intake into two daily intakes. The objective of this
multicentre, randomized, open-label phase IV study, was
to demonstrate the non-inferiority, in terms of clinical
and parasitological efficacy on D14, of the administration
of artesunate/amodiaquine as a single daily intake versus
two daily intakes. The safety and tolerability of treatment
were also studied.
Methods
Study area and population
The study took place in three sites, two in south Senegal,
where the climate is soudanian and the rainy season con-
centrated between June and October and one site in cen-
tral Cameroon with a sub-equatorial climate, the rainy
season is from April to November.
Any adults or children weighing ≥ 10 kg, able to receive
oral treatment, suffering from uncomplicated malaria
attack with parasitaemia ranging from 1,000 to 200,000/
μl (moderate and high transmission area) and axillary
temperature ≥ 37.5°C or history of fever within the previ-
ous 24 hours, was enrolled after signed informed consent.
Patients could not be included in the study if at least one
sign of severe malaria or clinical danger (WHO definition)
was present: serious concomitant disease, allergy to one of
the investigational medicinal products, pregnancy, or
documented intake of an antimalarial at a suitable dosage
within seven days prior to inclusion.
An ethical approval was given by the Conseil National de
Recherche en Santé in Senegal and the Comité National
d'Ethique  in Cameroon on 17 June 2005 and 23 May
2005, respectively.
Determination of sample size
Based on previous studies, with the hypotheses P1 = 99%
as the envisaged response rate for artesunate plus amodi-
aquine single dose (reference), a non-inferiority limit of
3%, a type I (α) error probability of 5% and a type II (β)
error probability of 20%, the number of patients per
group corresponded to 136. In order to anticipate prema-
ture withdrawals, a decision was made to include 150
patients per group, i.e. a total of 300 patients. Each site
was, therefore, required to recruit 100 patients. In order to
avoid any imbalance between the different weight catego-
ries, the randomization list was drawn up by centre and by
weight range.
Intervention
During the inclusion visit (D0), a physical examination
was performed with recording of medical history, demo-
graphic data (age, gender), weight and height, and meas-
urement of vital signs (blood pressure, pulse in the supine
position), and axillary's temperature, together with evalu-
ation of symptoms. Parasitological tests (blood films,
gametocytaemia) together with PCR filter paper were also
performed.
Follow-up visits took place on D1, D2, D3, D7 and D14
during which a physical examination was performed, with
evaluation of clinical safety and symptoms, measurement
of vital signs, and parasitological tests (except on D1 and
D2). Filter paper blood spot samples were prepared onMalaria Journal 2008, 7:16 http://www.malariajournal.com/content/7/1/16
Page 3 of 9
(page number not for citation purposes)
D14, if the thick blood film result was positive, with a
view to PCR analysis.
Since the artesunate plus amodiaquine coblisters contain
one tablet of 50 mg artesunate and one tablet of 153 mg
amodiaquine, dosages had to be adapted to the patient
weight range: patients weighing between 10 and 21 kg
received one tablet of each product per day, patients
weighing ≥ 21 and ≤ 40 kg received two tablets of each
product per day and patients weighing >40 kg received 4
tablets of each product per day. According to randomiza-
tion, tablets were given either once or twice a day. The
duration of treatment was three days in the two groups.
Each patient was randomly allocated to one of the study
groups, according to a pre-defined randomization list. The
tablets were administered with a small amount of water.
For the younger children, the tablets were crushed and
administered with water. All treatments were adminis-
tered in the presence of nursing staff. The patients stayed
at the centre for 30 minutes after administration, for
observation. If the patient rejected the treatment during
the observation period, the same dose was re-adminis-
tered. In the event of repeated vomiting, the patient had
to be withdrawn from the study and a replacement treat-
ment had to be introduced. All possible steps were imple-
mented in order to avoid losing patients to follow-up:
active follow-up, even going as far as the patient's home,
was carried out by a member of the principal investigator's
team.
Parasitological assessment
Thick films together with thin blood films were prepared
at each study visit with the exception of D1. A molecular
biology analysis (PCR) was performed on inclusion and
on D14 +/- 1d in the event of a positive thick film on D14
+/- 1d. Slide-reading and parasite counts were performed
on site and considered as negative in absence of asexual P.
falciparum form after examination of 300 leucocytes; 10%
of the slides were re-read at the centre's reference Parasi-
tology Department at Dakar University.
The molecular biology analyses were performed at the
parasitology laboratory at the Faculty of Medicine, Uni-
versité Cheikh Anta Diop Dakar – Senegal using filter
paper blood spot samples prepared in the field. The dis-
tinction of reinfections or recrudescence cases was carried
out using genetic markers for msp-1, msp-2 and microsat-
ellites
Statistical analysis
Independent duplicate data entry was performed using
the SAS software program, version 8.2, in compliance
with the standards stipulated by GCP guidelines. All of the
qualitatives and quantitatives variables recorded were
described according to treatment group and globally. The
95% confidence intervals were calculated.
The non-inferiority of artesunate plus amodiaquine as
two intakes versus artesunate plus amodiaquine as a sin-
gle intake was studied on the basis of the adequate
response to treatment on D14 (WHO definition). The
two-sided 90% confidence interval of the difference in the
proportions of responders on D14 between the two treat-
ment groups was calculated. If the upper limit of the con-
fidence interval was below the acceptance limit (d = 3%),
the non-inferiority of artesunate plus amodiaquine in two
intakes versus a single intake would be demonstrated.
This analysis was conducted on the ITT and per protocol
(PP) populations. The main analysis corresponded to the
ITT population.
The safety of artesunate plus amodiaquine was evaluated
by the presence or absence of adverse events, type of
adverse event, intensity and the causal relationship with
the investigational product in the safety population.
Results
From June to October 2005, 316 patients were included in
the study. 161 patients were assigned to the artesunate
plus amodiaquine single-intake treatment group (refer-
ence) and 155 to the artesunate plus amodiaquine two-
intake treatment group. Seven patients were withdrawn
from the study: five patients in the single-intake group
and two in the two-intake groups. Only one patient (in
the single-intake group) was withdrawn due to an adverse
event, five patients were withdrawn because of loss to fol-
low up and one because of consent withdrawn (Figure 1)
On inclusion, the patients in the two treatment groups
presented similar data (Table 1), with a mean body tem-
perature (± standard deviation) of 38.30°C (± 1.01°C),
median values of parasitaemia equal to 16,421.0 para-
sites/μl in the single-intake group versus 13,750.0 para-
sites/μl in the two-intake group.
Efficacy outcome
The primary efficacy endpoint was the adequate response
to treatment after PCR analysis (ACPRc). Irrespective of
treatment regimen, more than 99% of patients showed an
adequate clinical and parasitological response.
The results of the evaluation of efficacy on D14 before
PCR and after PCR on the ITT population are presented on
Table 2. The two-sided 90% confidence interval of the dif-
ference in the proportion of PCR corrected adequate clin-
ical and parasitological response (ACPRc) between the
two treatment groups was: (-3.00; 1.11]. The upper limit
of the confidence interval (1.11%) was below the accept-
ance limit, d = 3%., assessing that the two intakes treat-Malaria Journal 2008, 7:16 http://www.malariajournal.com/content/7/1/16
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ment regimen is non-inferior to the single intake
treatment regimen on the ITT population. These results
were confirmed on the PP population.
The changes in mean temperature during the study were
similar in the two treatment groups, with values for mean
temperature below 37.5°C as from D1. The percentage of
apyretic patients between D1 and D14 is shown in
Figure 2. Between D2 and D14, the number of patients
with negative parasitaemia increased in a similar manner
in the two treatment groups: from approximately 70% on
D2 to more than 99% on D14.
Gametocyte-carrier patients were 12 on inclusion, D7 and
D14, and 14 on D3. The mean values for gametocytaemia
were halved between D1 and D7 in both groups. With the
exception of anorexia wich mainly affected patients under
seven years of age in the two treatment groups, and was on
D1 statistically higher in the single-intake group (37.9%
versus 28.3%, p = 0.0389). A similar and favourable out-
come, with regard to the symptoms of malaria, was
observed for the two patient groups during the study. The
changes in the percentage of patients in each group pre-
senting these symptoms are shown in the Table 3.
Safety outcome
Certain symptoms attributable to malaria, but not present
on inclusion, appeared during treatment: asthenia
(5.7%), vomiting (4.7%), anorexia (4.7%), diarrhoea
(2.8%), abdominal pain (1.9%) and dizziness (2.2%),
without any differences between the treatment groups.
The influence of the number of tablets per intake, or the
total quantity of drug substance to be ingested, on the
onset of these symptoms was the subject of a descriptive
analysis only, owing to the limited sample size.
With the exception of two patients prematurely with-
drawn from the study in the single-intake group (one for
consent withdrawn, the other for bronchopneumopathy),
who only received treatment for one day, all of the other
patients received treatment for three days, as provided for
in the protocol. The adverse events (AE) recorded during
the study were coded in compliance with the MedDRA
dictionary, and described for the safety population.
Among the population included, the AEs reported during
the study mainly corresponded to gastrointestinal disor-
ders (2.5%) or pruritus (2.5%), irrespective of the treat-
ment regimen. Three patients in the two-intake group
reported AEs related to nervous system disorders (two
cases of drowsiness and one case of dysgeusia – bitter
taste) versus one patient in the single-intake group (one
case of seizure). All of the gastrointestinal or nervous sys-
tem disorders and cases of pruritus reported during the
study were perceived as related to the investigational
product, irrespective of treatment regimen. Intensity of
adverse events reported as being related to the investiga-
tional product is shown in Table 4.
Study design (*) Figure 1
Study design. (*) Two patients did not undergo a parasite 
evaluation between D3 and D14 (patients withdrawn from 
the study). (**) 11 patients presented major deviations and 
five patients did not complete the study. Five patients, three 
in the single-intake group and two in the two-intake group, 
did not undergo an evaluation on D14. These patients moved 
out of the area covered by the investigating centre before 
the end of the study.
Patients included N=316
Patients excluded N = 0
Safety population N = 316
One intake N = 161
Two intakes N = 155
Patients excluded N = 2*
ITT population N= 314 
(99.4%)
One intake N = 159
Two intakes N = 155
Patients excluded 
N = 16**
PP population N= 298 
(94.3%)
One intake N = 148
Two intakes N = 150Malaria Journal 2008, 7:16 http://www.malariajournal.com/content/7/1/16
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Two serious adverse events occurred during the study, one
in each treatment regimen; they were both perceived as
unrelated to the investigational product. No death
occurred during this study.
Rejection of treatment during the first half-hour after
administration was observed in 10 patients, six in the
artesunate plus amodiaquine single-intake group and four
in the two-intake group, mainly occurring on D0
(Table 5). Out of these 10 patients, seven were aged
between six and 13 years. No differences were observed
between the two patient groups. An equivalent dose of
treatment was re-administered in each case. It should be
noted that all patients presented episodes of vomiting in
the 24 hours prior to inclusion. The influence, on early
treatment rejection, of the number of tablets to be
ingested was the subject of a descriptive analysis only
owing to the limited sample size.
Fifteen patients presented episodes of vomiting during the
treatment period although this symptom was not
observed on inclusion: seven patients (4.3%) in the sin-
gle-intake group and eight patients (5.2%) in the two-
intake group. It should be noted that this description does
not take early treatment rejection into account. All these
patients presented at least one of vomiting in the previous
24 hours. The number of tablets taken by the 15 patients
concerned is shown in the Table 6.
The episodes of vomiting during treatment appear to have
been influenced by the number of tablets taken each day.
Dose fractionation does not appear to have any impact on
the number of patients having presented this symptom
during treatment. However, no conclusions may be drawn
owning to the limited sample size in these subgroups.
Discussion
The correct prescription of ACT by healthcare staff and the
compliance of patients are essential for an effective man-
agement of malaria in Africa. Different previous studies
had already shown the efficacy and tolerability of artesu-
nate plus amodiaquine in sub-Saharan Africa [2-7].
Table 1: Clinical and parasitological baseline data on D0
Artesunate plus amodiaquine 
One intake/day
Artesunate plus amodiaquine 
Two intakes/day
Total
Patients 161 155 316
Male 97 (60.2%) 85 (54.8%) 182 (57.6%)
Female 64 (39.8%) 70 (45.2%) 134 (42.4%)
Age range
≤ 5 years 32 (19.9%) 26 (16.8%) 58 (18.4%)
From 6 to13 years 65 (40.4%) 63 (40.6%) 128 (40.5%)
≥ 14 years 64 (39.7%) 66 (42.6%) 130 (41.1%)
Parasite density/μL
Mean (SD) 41861.3 (75507.9) 31940.6 (42530.8) 36995.2 (61684.5)
Médian (Q1; Q3] 16421(6473; 45550] 13750(6240; 45217] 15423.0 (6356.5;45378.5]
Gametocytes/μL
Mean (SD) 21.9 (134.5) 18.8 (110.9) 20.4 (123.3)
Table 2: Evaluation of efficacy on D14 before PCR correction (ITT population)
Artesunate plus 
amodiaquine one intake
Artesunate plus 
amodiaquine two intakes
Total
ETF (Early treatment failure) 0 0 0
LCF (Late clinical failure) 0 0 0
LPF (Late parasitological failure) 1 (0.6%) 1 (0.7%) 2 (0.6%)
ACPR (Adequate clinical and parasitological response) 155 (99.4%) 152 (99.3%) 307 (99.4%)
ACPRc (Adequate clinical and parasitological response 
after PCR correction)
155 (99.4%) 153 (100.0%) 308 (99.7%)
NA 3 2 5
Note: "NA" = "Missing" patient not having undergone parasitological tests on D14.Malaria Journal 2008, 7:16 http://www.malariajournal.com/content/7/1/16
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Table 3: Changes in the percentage of patients presenting symptoms of malaria attack during the study
Symptoms Percentage of patients with symptoms 
on D0
Percentage of patients with symptoms 
on D3
Percentage of patients with symptoms 
on D14
One intake 
N = 161
Two intakes 
N = 155
One intake 
N = 161
Two intakes 
N = 155
One intake 
N = 161
Two intakes 
N = 155
Headache 88.8% 91.0% 5.0% 1.9% 0.6% 0.7%
Perspiration 59.0% 55.5% 10.6% 9.7% 1.2% 3.9%
Dizziness 42.2% 45.2% 8.7% 7.1% 0.6% 1.3%
Chills 69.6% 67.7% 3.1% 4.5% 0.6% 2.6%
Pain 41.6% 40.6% 5.7% 10.3% 1.9% 2.6%
Anorexia 70.8% 71.6% 19.8% 15.5% 1.2% 0
Asthenia 77.0% 74.8% 39.1% 38.7% 0.6% 0.6%
Jaundice 1.9% 0.6% 0.6% 0 0 0
Skinfold 0.6% 0.6% 1.3% 1.3% 0 0
Hepatomegaly 7.5% 5.8% 7.5% 3.9% 5.8% 3.9%
Vomiting in 24 hours 47.8% 43.9% 3.7% 2.5% 0 0
Diarrhoea in 24 hours 9.3% 8.4% 1.8% 2.5% 0 1.3%
Apyretic patients between D1 and D14 Figure 2
Apyretic patients between D1 and D14.
98.70%
(N=154)
99.40%
(N=158)
99.40%
(N=158) 91.80%
(N=146)
75.50%
(N=120)
98%
(N=150)
99.40%
(N=154)
99.40%
(N=154) 94.20%
(N=146)
72.90%
(N=113)
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
D1 D2 D3 D7 D14
Days
(%)
Arsucam one intake/day
Arsucam 2 intakes/day
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The objective of this pilot study was to verify the non-infe-
riority of two daily intakes versus a single intake (which
can permit to decrease the number of tablet to be taken
per dose) and to evaluate the impact of dose fractionation
on clinical safety
This study showed that adequate responses to treatment
were similar for the two treatment regimens, and
approaching 100% before and after PCR analysis on D14.
The statistical analyses conducted on the ITT and PP pop-
ulations demonstrated the non-inferiority of administer-
ing Artesunate plus amodiaquine as two intakes versus a
single daily intake, in terms of clinical and parasitological
efficacy on D14.
It was also demonstrated that the two tested treatment
regimen were well tolerated; the observed AEs were simi-
lar in terms of type and incidence in the two treatment
groups. No changes were observed in the safety profile
when dividing Artesunate plus amodiaquine treatment
into two daily intakes. The events reported during the
study were expected and have already been described with
this type of antimalarial.
Numerous papers described an impact of artemisinin
derivatives on gametocyte carriage, by killing immature
stages of gametocytes. During this study, the number of
gametocyte-carrier patients remained stable during fol-
low-up (from D0 to D14), but the mean values for game-
tocytaemia were halved between D1 and D7 in both
groups. This can possibly be explained by the presence of
different stage of gametocytes in the study populations.
The duration of follow-up of this study was only 14 days,
but the efficacy has been demonstrated in numerous other
studies within a D28 follow-up [2,4,5], and the impact of
dose fractionation should be observed only in the first
days after treatment. Since one of the objectives of the
study was to evaluate the impact of taking a large number
of tablets in one go on tolerability, no placebo was used
during the trial, and a double-blind double-dummy
scheme was not used, but treatment administration was
blinded for the investigators.
Conclusion
The combination artesunate plus amodiaquine has
already been adopted as first line treatment of uncompli-
cated malaria attack in 18 countries in sub-Saharan Africa,
with a regimen of one daily intake for three days. Even if
the tolerability profile remains good in the clinical trials,
in real life, some patients (mainly adults) complain about
the too important number of tablets to be ingested at
once. The results of this study will permit to divide the
daily intake into two administrations.
A fixed dose combination of these two active components
has already been developed and is currently being evalu-
ated in sub-Saharan Africa. This new formulation, with a
limited number of tablets per intake may allow a better
adherence to an effective treatment for African communi-
ties.
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Table 5: Number of patients having experienced early treatment 
rejection during the study
Number of 
patients with 
episodes of 
vomiting within 
30 minutes/
Number of 
tablets per day
One intake 
N = 161
One intakes 
N = 155
Total 
N = 316
248248
D 0 110130 6
D 1 020000 2
D 2 002000 2
T o t a l 132130 1 0
Table 6: Number of tablets taken by patients with episodes of 
vomiting during treatment only
Number of 
tablets per day
One intake 
N = 161
Two intakes
 N = 155
Total N = 316
2  t a b l e t s000
4 tablets 1 (0.6%) 4 (2.6%) 5 (1.6%)
8 tablets 6 (3.7%) 4 (2.6%) 10 (3.2%)
Total 7 (4.3%) 8 (5.2%) 15 (4.8%)
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